NewsBenzinga서로젠, FDA 제출로 주력 치료제 개발에 박차 서로젠, FDA 제출로 주력 치료제 개발에 박차 Benzinga 2026.09.24 15:41 (GMT+0) Open on Benzinga Other news Roth Capital Initiates Coverage On Energy Servs of America with Buy Rating, Announces Price Target of $20 Mizuho Maintains Neutral on Okta, Raises Price Target to $200 Mizuho Maintains Neutral on Regency Centers, Lowers Price Target to $76 Mizuho Maintains Outperform on Phillips Edison & Co, Lowers Price Target to $39 Mizuho Maintains Neutral on Kimco Realty, Lowers Price Target to $23 8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Roth Capital Initiates Coverage On Energy Servs of America with Buy Rating, Announces Price Target of $20
